Firmonertinib Mesilate Tablets

DRUG2 trials

Sponsors

Allist Pharmaceuticals, Inc., Peking University Cancer Hospital & Institute

Conditions

EGFREGFR Activating MutationNSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)Resectable Lung Non-Small Cell Carcinoma

Phase 2

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

Not yet recruitingNCT07182708

Peking University Cancer Hospital & InstituteEGFR Activating Mutation, NSCLC (Non-small Cell Lung Cancer), Resectable Lung Non-Small Cell Carcinoma

Start: 2025-10-01End: 2030-06-30Target: 62Updated: 2025-09-19

Phase 3

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

RecruitingNCT06956001

Allist Pharmaceuticals, Inc.EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2024-11-19End: 2028-07-01Target: 300Updated: 2026-02-12